 |
 |
 |
|
|
|||
|
|
||||
|
||||
Insmed Research UpdateFrom: PCOSA (anonymous@obgyn.net)Wed, 13 Dec 2000 18:34:38 -0600
Insmed Incorporated Announces Preliminary Data From Two Clinical Trials RICHMOND, Va.--(BUSINESS WIRE)--Nov. 24, 2000--Insmed Incorporated today announced it has received preliminary data for two clinical trials. Initial data from the SomatoKine(R) Type 2 diabetes trial demonstrated that SomatoKine, whether delivered via continuous infusion or subcutaneous injection, reduced insulin consumption and average daily blood glucose levels in Type 2 diabetics. SomatoKine has previously demonstrated similar effects in patients with Type 1 diabetes. "We are pleased to extend the positive SomatoKine results previously obtained from the treatment of patients with Type 1 diabetes to the much larger population of Type 2 diabetics, and confirm the insulin-sensitizing properties of SomatoKine," said Geoffrey Allan, Ph.D., President and CEO of Insmed Incorporated. In a separate trial, a preliminary intent-to-treat analysis showed that Type 2 diabetics treated with INS-1 in combination with sulfonylureas showed no statistical significance from placebo. "The data is preliminary and inconsistent with our previous trials for both Type 2 diabetes and polycystic ovarian syndrome," commented Dr. Allan. "We intend to evaluate each patient in detail to understand the significance of this data," he said. About Insmed Incorporated: Insmed Incorporated is a biopharmaceutical company focused on the discovery and development of pharmaceutical products for the treatment of metabolic diseases and endocrine disorders associated with insulin resistance. Further information is available at http://www.insmed.com.
-- Director of Media Relations Polycystic Ovarian Support Association, Inc. (PCOSA) pr@pcosupport.org
|
|
Return to ![[ PCOS Discussion Forums ]](../../images/pcos_at_obgyn.gif)
Technical Problems: webmaster@obgyn.net
Last Updated: Mon May 19 16:23:04 2008